Advertisement

Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism

  • Tatjana Traub-Weidinger
  • Daniel Putzer
  • Elisabeth von Guggenberg
  • Georg Dobrozemsky
  • Bernhard Nilica
  • Dorota Kendler
  • Reto Bale
  • Irene Johanna VirgoliniEmail author
Original Article

Abstract

Purpose

Radiolabelled somatostatin (SST) analogues have proven useful in diagnosing tumours positive for SST receptor (SSTR). As different subtypes of SSTR are expressed on the tumour cell surface, the choice of appropriate therapeutic SST analogue is crucial. We evaluated the SSTR status of thyroid cancer patients who had signs of progressive disease comparing different SSTR ligands for PET imaging to evaluate possible further therapeutic options.

Methods

PET with 68Ga-radiolabelled SSTR ligands DOTA lanreotide (DOTA-LAN), DOTA-Tyr3 octreotide (DOTA-TOC) and 18F-FDG was performed in 31 patients with thyroid cancer (TC). These 31 patients comprised 18 with radioiodine non-avid differentiated TC (DTC) including 6 papillary TC (PTC), 8 follicular TC (FTC) and 4 oxyphilic TC (oxyTC), 5 with anaplastic TC (ATC), and 8 with medullary TC (MTC). The PET results were compared in a region-based evaluation.

Results

All patients underwent a PET study with 68Ga-DOTA-LAN, 28 patients with 68Ga-DOTA-TOC and 28 patients with 18F-FDG. A lack of SSTR expression was found in 13 of the 31 patients (42 %) with negative results with both SSTR tracers in 12 patients. Ambiguous results with both SSTR tracers were observed in one patient. High tracer uptake in SSTR PET images was seen in seven DTC patients (39 %; two PTC, three FTC, two oxyTC), in four ATC patients (80 %) and in six MTC patients (75 %). Lesions showing aerobic glycolysis on 18F-FDG PET were found in 24 of 28 patients (86 %) with corresponding positive results with 68Ga-DOTA-LAN in 35 % and with 68Ga-DOTA-TOC in 29 %.

Conclusion

The heterogeneous SSTR profile of TC tumour lesions needs to be evaluated using different SSTR PET tracers to characterize more closely the SSTR subtype affinities in patients with progressive TC in order to further stratify therapy with SSTR therapeutics.

Keywords

68Ga-DOTA-LAN 68Ga-DOTA-TOC Thyroid cancer Somatostatin receptor PET imaging 

Notes

Compliance with ethical standards

Conflicts of Interest

None.

Informed consent

This study was retrospective in nature and formal consent was not required. All patients gave written informed consent before undergoing each of the imaging modalities according to institutional guidelines.

References

  1. 1.
    Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.CrossRefPubMedGoogle Scholar
  2. 2.
    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–69.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1997;82:1857–62.PubMedGoogle Scholar
  6. 6.
    Forssell-Aronsson EB, Nilsson O, Bejegård SA, Kölby L, Bernhardt P, Mölne J, et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41:636–42.PubMedGoogle Scholar
  7. 7.
    Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:1144–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001;24:415–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E, et al. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31:330–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a pilot study. Nucl Med Commun. 2001;22:673–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Görges R, Kahaly G, Müller-Brand J, Mäcke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogs for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid. 2001;11:647–59.CrossRefPubMedGoogle Scholar
  13. 13.
    Hofmann M, Maecke H, Borner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med. 1998;39:1928–36.PubMedGoogle Scholar
  15. 15.
    Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, et al. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging. 2010;54:52–60.PubMedGoogle Scholar
  16. 16.
    Petrik M, Knetsch PA, Knopp R, Imperato G, Ocak M, von Guggenberg E, et al. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl Med Commun. 2011;32:887–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Siegel R, Miller K, Jemal A. Cancer statistics 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMedGoogle Scholar
  18. 18.
    Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76(6):1413–7.PubMedGoogle Scholar
  19. 19.
    Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarc'h J, Herry JY, et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med. 1998;25:687–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F. Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans. Eur J Endocrinol. 2004;150:277–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology. 1999;140:5136–48.PubMedGoogle Scholar
  22. 22.
    Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Middendorp M, Selkinski I, Happel C, Kranert WT, Grünwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54(1):76–83.PubMedGoogle Scholar
  24. 24.
    Mato E, Matías-Guiu X, Chico A, Webb SM, Cabezas R, Berná L, et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:2417–20.PubMedGoogle Scholar
  25. 25.
    Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, et al. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analog. Thyroid. 2000;10:177–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Kohlfuerst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E, Matschnig S, et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? Thyroid. 2006;16:1113–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009;115:2052–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Versari AL, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24(4):715–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Klein Hesselink EN, Steenvoorden D, Kapiteijn E, Corssmit EP, van der Horst-Schrivers AN, Lefrandt JD, et al. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172(5):R215–25.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Tatjana Traub-Weidinger
    • 1
    • 2
  • Daniel Putzer
    • 3
  • Elisabeth von Guggenberg
    • 2
  • Georg Dobrozemsky
    • 2
  • Bernhard Nilica
    • 2
  • Dorota Kendler
    • 2
  • Reto Bale
    • 3
  • Irene Johanna Virgolini
    • 2
    Email author
  1. 1.Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided TherapyMedical University of ViennaViennaAustria
  2. 2.Department of Nuclear MedicineMedical University of InnsbruckInnsbruckAustria
  3. 3.Department of RadiologyMedical University of InnsbruckInnsbruckAustria

Personalised recommendations